Correlation Between TransAKT and Canopus BioPharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both TransAKT and Canopus BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining TransAKT and Canopus BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between TransAKT and Canopus BioPharma Incorporated, you can compare the effects of market volatilities on TransAKT and Canopus BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in TransAKT with a short position of Canopus BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of TransAKT and Canopus BioPharma.

Diversification Opportunities for TransAKT and Canopus BioPharma

0.1
  Correlation Coefficient

Average diversification

The 3 months correlation between TransAKT and Canopus is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding TransAKT and Canopus BioPharma Incorporated in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Canopus BioPharma and TransAKT is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on TransAKT are associated (or correlated) with Canopus BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Canopus BioPharma has no effect on the direction of TransAKT i.e., TransAKT and Canopus BioPharma go up and down completely randomly.

Pair Corralation between TransAKT and Canopus BioPharma

Given the investment horizon of 90 days TransAKT is expected to under-perform the Canopus BioPharma. But the pink sheet apears to be less risky and, when comparing its historical volatility, TransAKT is 1.79 times less risky than Canopus BioPharma. The pink sheet trades about -0.22 of its potential returns per unit of risk. The Canopus BioPharma Incorporated is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  0.02  in Canopus BioPharma Incorporated on October 17, 2024 and sell it today you would lose (0.01) from holding Canopus BioPharma Incorporated or give up 50.0% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy95.0%
ValuesDaily Returns

TransAKT  vs.  Canopus BioPharma Incorporated

 Performance 
       Timeline  
TransAKT 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in TransAKT are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent forward-looking signals, TransAKT exhibited solid returns over the last few months and may actually be approaching a breakup point.
Canopus BioPharma 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Canopus BioPharma Incorporated are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile forward indicators, Canopus BioPharma sustained solid returns over the last few months and may actually be approaching a breakup point.

TransAKT and Canopus BioPharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with TransAKT and Canopus BioPharma

The main advantage of trading using opposite TransAKT and Canopus BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if TransAKT position performs unexpectedly, Canopus BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Canopus BioPharma will offset losses from the drop in Canopus BioPharma's long position.
The idea behind TransAKT and Canopus BioPharma Incorporated pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated